Twist bioscience and ginkgo bioworks revise collaboration

South san francisco, calif. & boston--(business wire)--twist bioscience corporation (nasdaq: twst), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. under the terms of the revised three-year $15 million agr.
DNA Ratings Summary
DNA Quant Ranking